GILD – gilead sciences, inc. (US:NASDAQ)
Stock Stats
News
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive [Yahoo! Finance]
Vantis Health completes €10m funding round to advance primary care [Yahoo! Finance]
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Morgan Stanley from $123.00 to $130.00. They now have an "overweight" rating on the stock.
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Mercier Johanna
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: O'Day Daniel Patrick
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Telman Deborah H
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Dickinson Andrew D
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Patterson Sandra
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.